Company news

Neovasc Inc news in 2021

Neovasc Inc's news releases, calls and decks from 2021, newest first.

View company

Neovasc to Participate in Sidoti December Virtual Microcap Conference

December 1, 2021

Neovasc Reducer(TM) System Receives National Reimbursement in France

November 30, 2021

Neovasc Granted Additional 180 Calendar Day Grace Period for Nasdaq Bid Price Compliance

November 24, 2021

The National Institute for Health and Care Excellence of the United Kingdom Provides Positive Guidance for Neovasc Reducer System

November 24, 2021

Neovasc Announces Third Quarter 2021 Financial Results and Provides Corporate Update

November 9, 2021

Neovasc to Report Third Quarter 2021 Financial Results on November 9, 2021

November 1, 2021

Neovasc Reducer(TM) Featured in Polish Heart Journal

October 21, 2021

Neovasc REDUCER-I Study Published in EuroIntervention Journal

September 28, 2021

Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference

September 23, 2021

Neovasc Announces FDA Approval of COSIRA-II Clinical Trial

September 16, 2021

Neovasc to Participate in H.C. Wainwright & Co. 23rd Annual Global Investment Conference

August 30, 2021

Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA

August 17, 2021

Neovasc Announces Second Quarter 2021 Financial Results

August 10, 2021

Neovasc to Report Second Quarter 2021 Financial Results on August 10, 2021

July 27, 2021

Neovasc Announces New Appointments in Regulatory and Clinical Leadership

July 13, 2021

Largest Real-World Registry Supporting Neovasc Reducer(TM) Safety and Efficacy Outcomes Published in International Journal of Cardiology

June 18, 2021

Neovasc Provides Corporate Update

June 10, 2021

Neovasc Reducer System Receives First National Reimbursement in Europe

June 7, 2021

Neovasc Inc. Reports Results of Annual General Meeting of Shareholders

June 3, 2021

Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

May 25, 2021

Neovasc Provides Update on German Litigation

May 20, 2021

Neovasc to Sponsor Symposium on Reducer at EuroPCR

May 13, 2021

Neovasc Announces First Patient Enrollment in COSIMA Trial

May 10, 2021

Neovasc Announces First Quarter 2021 Financial Results

May 6, 2021

Neovasc Provides Reducer Reimbursement Progress Update

April 28, 2021

Neovasc to Report First Quarter 2021 Financial Results on May 6, 2021

April 27, 2021

Neovasc Comments on EuroIntervention Article

April 19, 2021

Neovasc Provides Tiara TA Update

April 16, 2021

Neovasc Announces Fourth Quarter and Fiscal Year 2020 Financial Results

March 11, 2021

Neovasc to Report Fourth Quarter and Fiscal Year 2020 Results on March 11, 2021

March 4, 2021

Neovasc to Participate in 2021 H.C. Wainwright Global Life Sciences Conference

March 3, 2021

Neovasc Comments on Clinical Cardiology Journal Publication

March 2, 2021

Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

February 24, 2021

Neovasc to Participate in 10th Annual SVB Leerink Global Healthcare Conference

February 17, 2021

Neovasc Announces Closing of US$72 Million Registered Direct Offering of Common Shares Priced At-The-Market

February 12, 2021

Neovasc Announces US$72 Million Registered Direct Offering Priced At-The-Market

February 10, 2021

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

February 9, 2021

Neovasc Comments on Journal of the American Heart Association Publication

February 5, 2021

Neovasc Announces 2021 Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina

February 2, 2021

American Medical Association Issues New CPT Code for Neovasc Reducer Procedure

January 29, 2021

Neovasc Reducer Featured in Three Peer Reviewed Publications Supporting Reducer Therapy

January 19, 2021

Neovasc Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer(TM)

January 15, 2021

Neovasc Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference

January 4, 2021